{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T01:29:06Z","timestamp":1772587746552,"version":"3.50.1"},"reference-count":33,"publisher":"American Diabetes Association","issue":"6","license":[{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6,2]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To compare the efficacy of low-dose subcutaneous dasiglucagon with oral glucose for prevention of insulin-induced hypoglycemia in people with type 1 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>Twenty adults with type 1 diabetes using multiple daily injection or insulin pump therapy completed a phase 2, randomized, three-arm crossover study. On each study visit, an individualized subcutaneous insulin bolus was administered aiming for a plasma glucose (PG) concentration of 3.0 mmol\/L (54 mg\/dL). When a PG concentration of 4.5 mmol\/L (81 mg\/dL) was reached, 15 g oral glucose (CHO) from dextrose tablets, 80 \u00b5g dasiglucagon (D80), or 120 \u00b5g dasiglucagon (D120) was administered. PG was measured frequently for the following 180 min.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Hypoglycemia (&amp;lt;3.9 mmol\/L [70 mg\/dL]) occurred in 10 participants after CHO, in 5 after D80, and in 4 after D120 (CHO vs. D80, P = 0.096; CHO vs. D120, P = 0.034). Time spent in hypoglycemia (&amp;lt;3.9 mmol\/L [70 mg\/dL]) was 14%, 7%, and 6% for CHO, D80, and D120, respectively (P = 0.273). The median time (95% CI) from intervention to first increase in PG of 1.1 mmol\/L (20 mg\/dL) was 30 (25\u201350), 15 (15\u201320), and 15 (15\u201320) minutes for CHO, D80, and D120, respectively (CHO vs. D80, P = 0.006; CHO vs. D120, P = 0.003). Episodes of nausea were numerically, but not significantly, higher after dasiglucagon administration. No significant differences in visual analog scale-assessed adverse effects were observed between interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Low-dose dasiglucagon safely and effectively prevented insulin-induced hypoglycemia with a faster glucose-elevating profile than oral glucose.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc21-2304","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T09:34:50Z","timestamp":1651052090000},"page":"1391-1399","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":10,"title":["Low-Dose Dasiglucagon Versus Oral Glucose for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes: A Phase 2, Randomized, Three-Arm Crossover Study"],"prefix":"10.2337","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9253-9457","authenticated-orcid":false,"given":"Christian","family":"Laugesen","sequence":"first","affiliation":[{"name":"1Clinical Research, Steno Diabetes Center Copenhagen, Gentofte, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2253-6071","authenticated-orcid":false,"given":"Ajenthen G.","family":"Ranjan","sequence":"additional","affiliation":[{"name":"1Clinical Research, Steno Diabetes Center Copenhagen, Gentofte, Denmark"},{"name":"2Danish Diabetes Academy, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6968-6675","authenticated-orcid":false,"given":"Signe","family":"Schmidt","sequence":"additional","affiliation":[{"name":"1Clinical Research, Steno Diabetes Center Copenhagen, Gentofte, Denmark"},{"name":"3Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1620-8271","authenticated-orcid":false,"given":"Kirsten","family":"N\u00f8rgaard","sequence":"additional","affiliation":[{"name":"1Clinical Research, Steno Diabetes Center Copenhagen, Gentofte, Denmark"},{"name":"4Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2022,4,27]]},"reference":[{"key":"2022060218533983200_B1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0022-3476(94)70190-3","article-title":"Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial","volume":"125","author":"Diabetes Control and Complications Trial Research Group","year":"1994","journal-title":"J Pediatr"},{"key":"2022060218533983200_B2","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2337\/diacare.18.3.361","article-title":"Adverse events and their association with treatment regimens in the diabetes control and complications trial","volume":"18","author":"The Diabetes Control and Complications Trial Research Group","year":"1995","journal-title":"Diabetes Care"},{"key":"2022060218533983200_B3","article-title":"Incidence of hypoglycemia overtreatment in the SHARE Real Life Use Population","author":"Nakamura"},{"key":"2022060218533983200_B4","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00125-020-05366-3","article-title":"The consequences of hypoglycaemia","volume":"64","author":"Amiel","year":"2021","journal-title":"Diabetologia"},{"key":"2022060218533983200_B5","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.diabres.2004.07.008","article-title":"Morbidity of hypoglycemia in type 1 diabetes","volume":"1","author":"Frier","year":"2004","journal-title":"Diabetes Res Clin Pract"},{"key":"2022060218533983200_B6","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3111\/13696998.2014.946992","article-title":"The psychosocial and financial impact of non-severe hypoglycemic events on people with diabetes: two international surveys","volume":"17","author":"Fulcher","year":"2014","journal-title":"J Med Econ"},{"key":"2022060218533983200_B7","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.2337\/dc21-S006","article-title":"Glycemic targets: Standards of Medical Care in Diabetes\u20142021","volume":"44","author":"American Diabetes Association","year":"2021","journal-title":"Diabetes Care"},{"key":"2022060218533983200_B8","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.physbeh.2003.12.003","article-title":"Food cravings during acute hypoglycaemia in adults with Type 1 diabetes","volume":"80","author":"Strachan","year":"2004","journal-title":"Physiol Behav"},{"key":"2022060218533983200_B9","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/dom.13197","article-title":"Non-severe hypoglycaemia is associated with weight gain in patients with type 1 diabetes: results from the Diabetes Control and Complication Trial","volume":"20","author":"Bumbu","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2022060218533983200_B10","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1464-5491.2010.02956.x","article-title":"Temporal patterns in overweight and obesity in Type 1 diabetes","volume":"27","author":"Conway","year":"2010","journal-title":"Diabet Med"},{"key":"2022060218533983200_B11","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/archinternmed.2009.193","article-title":"Modern-day clinical course of type 1 diabetes mellitus after 30 years\u2019 duration: the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications experience (1983-2005)","volume":"169","author":"Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications (DCCT\/EDIC) Research Group","year":"2009","journal-title":"Arch Intern Med"},{"key":"2022060218533983200_B12","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/ijo.2009.75","article-title":"Adiposity and mortality in type 1 diabetes","volume":"33","author":"Conway","year":"2009","journal-title":"Int J Obes"},{"key":"2022060218533983200_B13","doi-asserted-by":"crossref","first-page":"e3409","DOI":"10.1002\/dmrr.3409","article-title":"Glucagon for hypoglycaemia treatment in type 1 diabetes","volume":"37","author":"Ranjan","year":"2021","journal-title":"Diabetes Metab Res Rev"},{"key":"2022060218533983200_B14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11892-019-1216-4","article-title":"Novel preparations of glucagon for the prevention and treatment of hypoglycemia","volume":"19","author":"Hawkes","year":"2019","journal-title":"Curr Diab Rep"},{"key":"2022060218533983200_B15","first-page":"B544","article-title":"Glucagon treatment in type 1 diabetes \u2013 with focus on restoring plasma glucose during mild hypoglycemia","volume":"65","author":"Ranjan","year":"2018","journal-title":"Dan Med J"},{"key":"2022060218533983200_B16","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1210\/jc.2017-00591","article-title":"Efficacy and safety of mini-dose glucagon for treatment of nonsevere hypoglycemia in adults with type 1 diabetes","volume":"102","author":"Haymond","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2022060218533983200_B17","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/dom.12627","article-title":"Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes","volume":"18","author":"Ranjan","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"2022060218533983200_B18","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2337\/dc17-1402","article-title":"Pharmacokinetic and pharmacodynamic characteristics of dasiglucagon, a novel soluble and stable glucagon analog","volume":"41","author":"H\u00f6velmann","year":"2018","journal-title":"Diabetes Care"},{"key":"2022060218533983200_B19","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/dom.13562","article-title":"Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus","volume":"21","author":"H\u00f6velmann","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2022060218533983200_B20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"2022060218533983200_B21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annemergmed.2004.07.446","article-title":"Clinically significant changes in nausea as measured on a visual analog scale","volume":"45","author":"Hendey","year":"2005","journal-title":"Ann Emerg Med"},{"key":"2022060218533983200_B22","unstructured":"Zealand Pharma\n          . Zealand Pharma Announces FDA Approval of Zegalogue\u00ae (dasiglucagon) Injection for the Treatment of Severe Hypoglycemia in People with Diabetes. 22 March 2021. Accessed 6 November 2021. Available from: https:\/\/www.globenewswire.com\/news-release\/2021\/03\/22\/2197267\/0\/en\/Zealand-Pharma-Announces-FDA-Approval-of-Zegalogue-dasiglucagon-injection-for-the-Treatment-of-Severe-Hypoglycemia-in-People-with-Diabetes.html"},{"key":"2022060218533983200_B23","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.2337\/dc20-2995","article-title":"Dasiglucagon\u2014a next-generation glucagon analog for rapid and effective treatment of severe hypoglycemia: results of phase 3 randomized double-blind clinical trial","volume":"44","author":"Pieber","year":"2021","journal-title":"Diabetes Care"},{"key":"2022060218533983200_B24","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/pedi.13220","article-title":"Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial","volume":"22","author":"Battelino","year":"2021","journal-title":"Pediatr Diabetes"},{"key":"2022060218533983200_B25","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1111\/dom.14475","article-title":"Dasiglucagon, a next-generation glucagon analogue, for treatment of severe hypoglycaemia via an autoinjector device: Results of a phase 3, randomized, double-blind trial","volume":"23","author":"Bailey","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2022060218533983200_B26","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.2337\/dc20-1086","article-title":"Performance of the insulin-only iLet Bionic Pancreas and the bihormonal iLet using dasiglucagon in adults with type 1 diabetes in a home-use setting","volume":"44","author":"Castellanos","year":"2021","journal-title":"Diabetes Care"},{"key":"2022060218533983200_B27","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"key":"2022060218533983200_B28","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.2337\/diacare.16.11.1453","article-title":"The role of diet behaviors in achieving improved glycemic control in intensively treated patients in the Diabetes Control and Complications Trial","volume":"16","author":"Delahanty","year":"1993","journal-title":"Diabetes Care"},{"key":"2022060218533983200_B29","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jcjd.2016.05.008","article-title":"Treatment of hypoglycemia in adult patients with type 1 diabetes: an observational study","volume":"40","author":"Savard","year":"2016","journal-title":"Can J Diabetes"},{"key":"2022060218533983200_B30","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1007\/s13300-019-00696-x","article-title":"Preference for subcutaneously administered low-dose glucagon versus orally administered glucose for treatment of mild hypoglycemia: a prospective survey study","volume":"10","author":"Tetzschner","year":"2019","journal-title":"Diabetes Ther"},{"key":"2022060218533983200_B31","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2337\/dc15-2124","article-title":"Nonaqueous, mini-dose glucagon for treatment of mild hypoglycemia in adults with type 1 diabetes: a dose-seeking study","volume":"39","author":"Haymond","year":"2016","journal-title":"Diabetes Care"},{"key":"2022060218533983200_B32","unstructured":"U.S. Food and Drug Administration\n          . Gvoke summary basis of approval, application 212097: clinical review. Accessed 6 November 2021. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212097Orig1s000TOC.cfm"},{"key":"2022060218533983200_B33","unstructured":"Clinicaltrials.gov-registration of \u201cPen-Administered Low-Dose Dasiglucagon for Prevention and Treatment of Hypoglycemia in People With Type 1 Diabetes\u201d (NCT04764968). Accessed 6 November 2021. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04764968"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/45\/6\/1391\/684215\/dc212304.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/45\/6\/1391\/684215\/dc212304.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T14:55:34Z","timestamp":1654181734000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/45\/6\/1391\/145035\/Low-Dose-Dasiglucagon-Versus-Oral-Glucose-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,27]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,4,27]]},"published-print":{"date-parts":[[2022,6,2]]}},"URL":"https:\/\/doi.org\/10.2337\/dc21-2304","relation":{"has-preprint":[{"id-type":"doi","id":"10.2337\/figshare.19403831.v1","asserted-by":"object"},{"id-type":"doi","id":"10.2337\/figshare.19403831","asserted-by":"object"}]},"ISSN":["0149-5992"],"issn-type":[{"value":"0149-5992","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,27]]}}}